117 related articles for article (PubMed ID: 16551782)
1. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.
Hausmann R; Rettinger J; Gerevich Z; Meis S; Kassack MU; Illes P; Lambrecht G; Schmalzing G
Mol Pharmacol; 2006 Jun; 69(6):2058-67. PubMed ID: 16551782
[TBL] [Abstract][Full Text] [Related]
2. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.
Rettinger J; Braun K; Hochmann H; Kassack MU; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Neuropharmacology; 2005 Mar; 48(3):461-8. PubMed ID: 15721178
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
Kassack MU; Braun K; Ganso M; Ullmann H; Nickel P; Böing B; Müller G; Lambrecht G
Eur J Med Chem; 2004 Apr; 39(4):345-57. PubMed ID: 15072843
[TBL] [Abstract][Full Text] [Related]
4. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.
Braun K; Rettinger J; Ganso M; Kassack M; Hildebrandt C; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):285-90. PubMed ID: 11521173
[TBL] [Abstract][Full Text] [Related]
5. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.
Farmer LK; Schmid R; Evans RJ
J Biol Chem; 2015 Jan; 290(3):1559-69. PubMed ID: 25425641
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
Hechler B; Magnenat S; Zighetti ML; Kassack MU; Ullmann H; Cazenave JP; Evans R; Cattaneo M; Gachet C
J Pharmacol Exp Ther; 2005 Jul; 314(1):232-43. PubMed ID: 15792995
[TBL] [Abstract][Full Text] [Related]
7. Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
Suzuki E; Kessler M; Montgomery K; Arai AC
Mol Pharmacol; 2004 Dec; 66(6):1738-47. PubMed ID: 15448189
[TBL] [Abstract][Full Text] [Related]
8. Ectodomain lysines and suramin block of P2X1 receptors.
Sim JA; Broomhead HE; North RA
J Biol Chem; 2008 Oct; 283(44):29841-6. PubMed ID: 18765669
[TBL] [Abstract][Full Text] [Related]
9. Characterization of functional P2X(1) receptors in mouse megakaryocytes.
Ikeda M
Thromb Res; 2007; 119(3):343-53. PubMed ID: 16626790
[TBL] [Abstract][Full Text] [Related]
10. NF449, a novel picomolar potency antagonist at human P2X1 receptors.
Hülsmann M; Nickel P; Kassack M; Schmalzing G; Lambrecht G; Markwardt F
Eur J Pharmacol; 2003 May; 470(1-2):1-7. PubMed ID: 12787824
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
Ullmann H; Meis S; Hongwiset D; Marzian C; Wiese M; Nickel P; Communi D; Boeynaems JM; Wolf C; Hausmann R; Schmalzing G; Kassack MU
J Med Chem; 2005 Nov; 48(22):7040-8. PubMed ID: 16250663
[TBL] [Abstract][Full Text] [Related]
12. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
Meis S; Hamacher A; Hongwiset D; Marzian C; Wiese M; Eckstein N; Royer HD; Communi D; Boeynaems JM; Hausmann R; Schmalzing G; Kassack MU
J Pharmacol Exp Ther; 2010 Jan; 332(1):238-47. PubMed ID: 19815812
[TBL] [Abstract][Full Text] [Related]
13. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor.
Rettinger J; Schmalzing G; Damer S; Müller G; Nickel P; Lambrecht G
Neuropharmacology; 2000 Aug; 39(11):2044-53. PubMed ID: 10963748
[TBL] [Abstract][Full Text] [Related]
14. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
Horner S; Menke K; Hildebrandt C; Kassack MU; Nickel P; Ullmann H; Mahaut-Smith MP; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):1-13. PubMed ID: 16158305
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors.
Soto F; Lambrecht G; Nickel P; Stühmer W; Busch AE
Neuropharmacology; 1999 Jan; 38(1):141-9. PubMed ID: 10193905
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological properties of P2X3-receptors present in neurones of the rat dorsal root ganglia.
Rae MG; Rowan EG; Kennedy C
Br J Pharmacol; 1998 May; 124(1):176-80. PubMed ID: 9630357
[TBL] [Abstract][Full Text] [Related]
17. Modulation of neurotransmitter release by P2X and P2Y receptors in the rat spinal cord.
Heinrich A; Kittel A; Csölle C; Sylvester Vizi E; Sperlágh B
Neuropharmacology; 2008 Feb; 54(2):375-86. PubMed ID: 18063000
[TBL] [Abstract][Full Text] [Related]
18. Suramin analogues as subtype-selective G protein inhibitors.
Freissmuth M; Boehm S; Beindl W; Nickel P; Ijzerman AP; Hohenegger M; Nanoff C
Mol Pharmacol; 1996 Apr; 49(4):602-11. PubMed ID: 8609887
[TBL] [Abstract][Full Text] [Related]
19. P2X receptor activation elicits transporter-mediated noradrenaline release from rat hippocampal slices.
Papp L; Balázsa T; Köfalvi A; Erdélyi F; Szabó G; Vizi ES; Sperlágh B
J Pharmacol Exp Ther; 2004 Sep; 310(3):973-80. PubMed ID: 15084650
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking.
Wolf C; Rosefort C; Fallah G; Kassack MU; Hamacher A; Bodnar M; Wang H; Illes P; Kless A; Bahrenberg G; Schmalzing G; Hausmann R
Mol Pharmacol; 2011 Apr; 79(4):649-61. PubMed ID: 21191044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
